| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Omiganan targets bacterial and fungal cell membranes. As a cationic antimicrobial peptide, it interacts with the cytoplasmic membrane of Gram-positive and Gram-negative bacteria, causing changes in its polarity with subsequent destruction of the bacteria. The compound's mechanism involves disruption of membrane integrity, leading to cell lysis and death.
|
|---|---|
| ln Vitro |
Omiganan demonstrates potent in vitro broad-spectrum antimicrobial activity. It has activity against both gram-positive and gram-negative bacteria, as well as Candida spp. isolates. The spectrum of antimicrobial activity of omiganan pentahydrochloride (MBI 226) was assessed against 1,437 recent clinical bacterial isolates and 214 recent clinical yeast isolates. It exhibits bactericidal activity and antibiofilm activity.
|
| ln Vivo |
Bacterial numbers decrease statistically significantly when omaganan is used. Omiganan lowers the S. aureus, S. epidermidis, and C. albicans bacterial counts by 3.8, 2.2, and 2.3 log10 CFU/site, respectively. Omiganan exhibits notable dose-dependent action and quick bactericidal and fungicidal effects against a wide range of pathogenic organisms[2].
In vivo activity of omiganan has been demonstrated in animal models. Omiganan pentahydrochloride (MBI-226) has given good results both in vitro and in vivo. It has been tested in a topical gel for the prevention of catheter-related bloodstream infections. It is used in studies related to atopic rhinitis and has been investigated for the treatment of bacterial endophthalmitis. |
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for omiganan, as its mechanism involves membrane disruption rather than specific enzyme inhibition. Its antimicrobial activity is assessed using standard broth microdilution or agar dilution methods to determine minimum inhibitory concentrations (MICs) against bacterial and fungal isolates.
|
| Cell Assay |
In vitro cellular assays for omiganan involve culturing bacterial or fungal cells in the presence of varying concentrations of the peptide. Antimicrobial activity is assessed by measuring inhibition of growth using optical density measurements or colony counting. Membrane disruption can be assessed using membrane permeability assays or electron microscopy.
|
| Animal Protocol |
In vivo animal experiments for omiganan have been conducted in models of bacterial endophthalmitis. The peptide is administered topically or by injection, and efficacy is evaluated by measuring bacterial load in tissues or clinical outcomes. The peptide has also been tested in models for the prevention of catheter-related bloodstream infections.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for omiganan are limited. As a cationic peptide, its absorption, distribution, metabolism, and excretion properties would be influenced by its peptide nature. The compound has been tested in a topical gel formulation. Further pharmacokinetic studies are needed to determine its systemic exposure and elimination pathways.
|
| Toxicity/Toxicokinetics |
Toxicological data for omiganan are limited. As a cationic antimicrobial peptide, it is generally considered to have low toxicity, but comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Faccone D, et al. Antimicrobial activity of de novo designed cationic peptides against multi-resistant clinical isolates. Eur J Med Chem. 2014;71:31-35.
[2]. Rubinchik E, et al. Antimicrobial and antifungal activities of a novel cationic antimicrobial peptide, omiganan, in experimental skin colonisation models. Int J Antimicrob Agents. 2009;34(5):457-461. |
| Additional Infomation |
Omiganan has been investigated for the treatment of mupirocin-resistant MRSA skin infections.
Drug Indications It has been investigated for the treatment of bacterial infections and rosacea. Omiganan (CAS#: 204248-78-2) is a cationic antimicrobial peptide with 12 amino acids and a synthetic analog of indolicidin. It exhibits broad-spectrum antimicrobial and antibiofilm activity. The peptide has activity against both gram-positive and gram-negative bacteria and Candida spp.. Its primary mechanism involves disrupting bacterial cell membranes. It is for research use only. |
| Molecular Formula |
C90H127N27O12
|
|---|---|
| Molecular Weight |
1779.15
|
| Exact Mass |
1778.02
|
| CAS # |
204248-78-2
|
| Related CAS # |
204248-78-2;269062-93-3 (pentahydrochloride);
|
| PubChem CID |
16131445
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
10.118
|
| Hydrogen Bond Donor Count |
25
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
52
|
| Heavy Atom Count |
129
|
| Complexity |
3790
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)N3CCCC3C(=O)NC(CC4=CNC5=CC=CC=C54)C(=O)NC(CC6=CNC7=CC=CC=C76)C(=O)N8CCCC8C(=O)NC(CC9=CNC1=CC=CC=C19)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCCN)C(=O)N)N
|
| InChi Key |
MVPAMLBUDIFYGK-BHDRXCTLSA-N
|
| InChi Code |
InChI=1S/C90H127N27O12/c1-5-51(4)75(92)85(127)113-68(41-50(2)3)80(122)109-67(32-18-38-102-90(98)99)79(121)114-71(44-54-48-105-62-27-12-8-23-58(54)62)86(128)116-39-19-34-74(116)84(126)112-70(43-53-47-104-61-26-11-7-22-57(53)61)82(124)115-72(45-55-49-106-63-28-13-9-24-59(55)63)87(129)117-40-20-33-73(117)83(125)111-69(42-52-46-103-60-25-10-6-21-56(52)60)81(123)110-66(31-17-37-101-89(96)97)78(120)108-65(30-16-36-100-88(94)95)77(119)107-64(76(93)118)29-14-15-35-91/h6-13,21-28,46-51,64-75,103-106H,5,14-20,29-45,91-92H2,1-4H3,(H2,93,118)(H,107,119)(H,108,120)(H,109,122)(H,110,123)(H,111,125)(H,112,126)(H,113,127)(H,114,121)(H,115,124)(H4,94,95,100)(H4,96,97,101)(H4,98,99,102)/t51-,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-amino-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-N-[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(2S)-1,6-diamino-1-oxohexan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 50 mg/mL (28.10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5621 mL | 2.8103 mL | 5.6207 mL | |
| 5 mM | 0.1124 mL | 0.5621 mL | 1.1241 mL | |
| 10 mM | 0.0562 mL | 0.2810 mL | 0.5621 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
